Ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation, plays a critical role in the initiation and progression of many major diseases. However, early detection of ferroptosis has long been a significant challenge in the research community.
Bio-Vision Technology, in collaboration with Professor Yang Youjun, introduces the LHA Series Ferroptosis Early Detection Fluorescent Probes – developed from groundbreaking research published in the Journal of the American Chemical Society (JACS). The series includes LHA585 (Red), LHA675 (Deep Red), and LHA930 (Near-Infrared) – specifically designed to precisely capture the initiating signal of ferroptosis: lipid hydrogen abstraction.
Core Advantages
True Early Detection
Unlike traditional probes that detect lipid peroxidation end-products, LHA probes target the earliest upstream event of ferroptosis. They generate fluorescence signals approximately 8 hours earlier than gold standard methods, providing a crucial time window for early disease diagnosis and intervention.
Exceptional Specificity and Sensitivity
The probe design cleverly mimics the structure of polyunsaturated fatty acids, enabling specific recognition and response to highly oxidizing radicals generated during ferroptosis, achieving up to a 360-fold fluorescence turn-on with extremely low background signal.
Superior Optical Performance
Available in multiple fluorescence channels – red, deep red, and near-infrared – to meet different experimental needs. LHA930, with its near-infrared emission, offers deeper tissue penetration and lower phototoxicity.
Excellent Photostability
LHA probes exhibit outstanding resistance to photobleaching, ensuring stable and reliable signals during long-term imaging experiments while avoiding the photoconversion issues commonly seen with traditional probes.
Application Scenarios
Disease Mechanism Research
In-depth exploration of ferroptosis mechanisms in ischemia-reperfusion injury (such as stroke and myocardial infarction), non-alcoholic fatty liver disease, neurodegenerative diseases (such as Alzheimer's disease), cancer development, and therapy resistance.
Drug Development and Screening
As a powerful tool for screening and evaluating potential therapeutic drugs that modulate the ferroptosis pathway.
Basic Biological Research
Studying the interplay between ferroptosis and other cell death pathways, as well as its physiological functions in cellular homeostasis maintenance.
Frequently Asked Questions (FAQ)
Q1: What makes LHA probes different from traditional ferroptosis detection methods?
A1: Traditional methods typically detect lipid peroxidation end-products such as malondialdehyde (MDA) or 4-hydroxynonenal (4-HNE). These are late-stage events. LHA probes detect lipid hydrogen abstraction – the earliest upstream initiating event of ferroptosis – providing a detection window approximately 8 hours earlier than gold standard methods.
Q2: How do LHA probes achieve such high specificity?
A2: LHA probes are designed to mimic the structure of polyunsaturated fatty acids, the primary targets of oxidative attack during ferroptosis. This allows them to specifically recognize and respond to highly oxidizing radicals generated at the very beginning of the ferroptosis pathway, resulting in high specificity and low background.
Q3: What is the fluorescence turn-on ratio of LHA probes?
A3: LHA probes can achieve up to a 360-fold fluorescence enhancement upon response to ferroptosis. This extremely high signal-to-noise ratio enables sensitive detection even in challenging biological samples.
Q4: What are the differences among LHA585, LHA675, and LHA930?
A4: The three probes offer different emission wavelengths:
-
LHA585: Red emission
-
LHA675: Deep red emission
-
LHA930: Near-infrared (NIR) emission
LHA930, with its NIR properties, offers deeper tissue penetration and lower phototoxicity, making it ideal for in vivo imaging applications.
Q5: What types of samples can LHA probes be used in?
A5: LHA probes are suitable for various sample types, including live cells, fixed cells, tissues, and potentially in vivo models. The specific sample compatibility may vary; consult the product datasheet or contact us for detailed recommendations.
Q6: Can LHA probes be used for high-throughput screening?
A6: Yes. The excellent fluorescence turn-on ratio and stable signal make LHA probes well-suited for high-content screening and drug discovery platforms.
Q7: How do LHA probes handle photostability?
A7: LHA probes demonstrate outstanding resistance to photobleaching. Unlike traditional probes that are easily photoactivated, LHA probes maintain stable fluorescence signals during extended imaging experiments, ensuring reliable data collection.
Q8: Do LHA probes require special storage conditions?
A8: Follow the product datasheet instructions. Generally, store protected from light at -20°C as specified. Avoid repeated freeze-thaw cycles.
Q9: What diseases can be studied using LHA probes?
A9: LHA probes are particularly useful for studying ferroptosis in ischemia-reperfusion injury (stroke, myocardial infarction), non-alcoholic fatty liver disease, neurodegenerative diseases (Alzheimer's, Parkinson's), cancer biology, and therapy resistance mechanisms.
Q10: Are LHA probes compatible with other fluorescent dyes for co-staining?
A10: Yes. LHA probes with their different emission channels (red, deep red, NIR) can be combined with green or blue probes for multicolor imaging, allowing simultaneous visualization of ferroptosis alongside other cellular markers.
Related Products：
- 9577416 LHA585 Ferroptosis fluorescent probe, 97%
- 9577417 LHA675, 97%
- 9577418 LHA930, 97%
艳 李
